Misa Kusumoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Misa Kusumoto has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bryan James Mathis
Department of Cardiovascular Surgery, University of Tsukuba, Tsukuba, Japan
2 shared publications - Akihiko Shimomura
Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan
1 shared publication - Alexander Zaboronok
Department of Neurosurgery, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Ibaraki, Japan
1 shared publication - Chikako Shimizu
Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan
1 shared publication - Soichiro Saeki
Division of Public Health, Department of Social Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
1 shared publication - Yuji Hiramatsu
Department of Cardiovascular Surgery, University of Tsukuba, Tsukuba, Japan
1 shared publication
Latest Publications
- 1 September 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (25) , 3061-3062
Shorter Duration of Trastuzumab Combined With Chemotherapy for Early Breast Cancer
- 1 September 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (25) , 3061-3062
Shorter Duration of Trastuzumab Combined With Chemotherapy for Early Breast Cancer
- Open Access
- 5 November 2023
- Published by Japan Epidemiological Association in Journal of Epidemiology
- Vol. 33 (11) , 589-590
Reporting Race and Ethnicity in Population Health and Clinical Research From Japan
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 5 November 2023
- Published by Japan Epidemiological Association in Journal of Epidemiology
- Vol. 33 (11) , 589-590
Open AccessReporting Race and Ethnicity in Population Health and Clinical Research From Japan
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 31 December 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (1) , 92
Packaging and Delivery of Asthma Therapeutics
Asthma is a life-altering, chronic disease of heterogenous origin that features a complex interplay of immune and environmental signaling. Although very little progress has been made in prevention, diverse types of medications and delivery systems, including nanoscale systems, have been or are currently being developed to control airway inflammation and prevent exacerbations and fibrosis. These medications are delivered through mechanical methods, with various inhalers (with benefits and drawbacks) existing, and new types offering some variety in delivery. Of particular interest is the progress being made in nanosized materials for efficient penetration into the epithelial mucus layer and delivery into the deepest parts of the lungs. Liposomes, nanoparticles, and extracellular vesicles, both natural and synthetic, have been explored in animal models of asthma and have produced promising results. This review will summarize and synthesize the latest developments in both macro-(inhaler) and micro-sized delivery systems for the purpose of treating asthma patients.
- 31 December 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (1) , 92
Open AccessPackaging and Delivery of Asthma Therapeutics
Asthma is a life-altering, chronic disease of heterogenous origin that features a complex interplay of immune and environmental signaling. Although very little progress has been made in prevention, diverse types of medications and delivery systems, including nanoscale systems, have been or are currently being developed to control airway inflammation and prevent exacerbations and fibrosis. These medications are delivered through mechanical methods, with various inhalers (with benefits and drawbacks) existing, and new types offering some variety in delivery. Of particular interest is the progress being made in nanosized materials for efficient penetration into the epithelial mucus layer and delivery into the deepest parts of the lungs. Liposomes, nanoparticles, and extracellular vesicles, both natural and synthetic, have been explored in animal models of asthma and have produced promising results. This review will summarize and synthesize the latest developments in both macro-(inhaler) and micro-sized delivery systems for the purpose of treating asthma patients.
- Open Access
Biologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder
The global COVID-19 pandemic has brought respiratory disease to the forefront of public health, but asthma prevalence has been rising globally for decades. Asthma is mediated by errant immune activation and airway remodeling, but the influences of environment, nutrition, and comorbidities (e.g., asthma-chronic obstructive pulmonary disorder-overlap [ACO]) are still poorly understood. Even as a new generation of biologic-based treatments offer better airway control and reductions in mortality, a lack of prophylactic treatments and mechanistic understanding complicates efforts to prevent pathogenesis. This review will explicate and synthesize current knowledge on the effect of ACO and biologics (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) on pathogenesis, treatment, and prognosis.
Open AccessBiologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder
The global COVID-19 pandemic has brought respiratory disease to the forefront of public health, but asthma prevalence has been rising globally for decades. Asthma is mediated by errant immune activation and airway remodeling, but the influences of environment, nutrition, and comorbidities (e.g., asthma-chronic obstructive pulmonary disorder-overlap [ACO]) are still poorly understood. Even as a new generation of biologic-based treatments offer better airway control and reductions in mortality, a lack of prophylactic treatments and mechanistic understanding complicates efforts to prevent pathogenesis. This review will explicate and synthesize current knowledge on the effect of ACO and biologics (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) on pathogenesis, treatment, and prognosis.